Baird’s Brian Skorney Discusses Sarepta and the FDA With Endpoints News
Brian Skorney, a Baird Senior Research Analyst covering biotechnology, was interviewed by Endpoints News’ Post-Hoc Live podcast. The conversation focuses on Sarepta Therapeutics and its controversial gene therapy for Duchenne muscular dystrophy. In addition, he discusses what it takes to get a drug to market, the role of the FDA, and implications for Sarepta’s future.
You can listen to the full discussion on Endpoints News, via Apple, YouTube, or Spotify.
